King Luther Capital Management Corp Invests $2.24 Million in TransMedics Group, Inc. $TMDX

King Luther Capital Management Corp purchased a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 20,000 shares of the company’s stock, valued at approximately $2,244,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Amalgamated Bank lifted its holdings in TransMedics Group by 0.8% in the second quarter. Amalgamated Bank now owns 9,586 shares of the company’s stock worth $1,285,000 after acquiring an additional 80 shares during the last quarter. Canada Pension Plan Investment Board raised its position in shares of TransMedics Group by 2.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after purchasing an additional 100 shares during the period. Smartleaf Asset Management LLC lifted its holdings in shares of TransMedics Group by 24.5% in the 2nd quarter. Smartleaf Asset Management LLC now owns 548 shares of the company’s stock worth $72,000 after purchasing an additional 108 shares during the last quarter. State of Wyoming boosted its position in TransMedics Group by 20.9% during the 3rd quarter. State of Wyoming now owns 683 shares of the company’s stock valued at $77,000 after purchasing an additional 118 shares during the period. Finally, TD Waterhouse Canada Inc. grew its stake in TransMedics Group by 26.5% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 601 shares of the company’s stock worth $69,000 after buying an additional 126 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Buying and Selling

In other news, insider Anil P. Ranganath sold 3,000 shares of TransMedics Group stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the transaction, the insider directly owned 13,955 shares in the company, valued at approximately $2,026,545.10. This trade represents a 17.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Gerardo Hernandez sold 920 shares of the company’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the sale, the chief financial officer owned 15,064 shares of the company’s stock, valued at approximately $2,103,235.68. This trade represents a 5.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 8,920 shares of company stock valued at $1,257,310 over the last quarter. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Stock Up 1.0%

TMDX stock opened at $134.25 on Friday. The firm’s 50-day moving average is $132.50 and its two-hundred day moving average is $125.87. The company has a market capitalization of $4.59 billion, a price-to-earnings ratio of 54.35 and a beta of 2.06. TransMedics Group, Inc. has a 52 week low of $62.07 and a 52 week high of $156.00. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43.

Analysts Set New Price Targets

TMDX has been the topic of a number of recent research reports. Canaccord Genuity Group raised their target price on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Piper Sandler reaffirmed an “overweight” rating on shares of TransMedics Group in a report on Monday, December 22nd. Morgan Stanley boosted their target price on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a report on Saturday, February 14th. Finally, Needham & Company LLC increased their price objective on TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $144.25.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.